Agnes Kant
Agnes Kant
Affiliation inconnue
Adresse e-mail validée de
Citée par
Citée par
Patient-reported safety information: a renaissance of pharmacovigilance?
L Härmark, J Raine, H Leufkens, IR Edwards, U Moretti, VM Sarinic, ...
Drug safety 39, 883-890, 2016
Description of frequencies of reported adverse events following immunization among four different COVID-19 vaccine brands
A Kant, J Jansen, L van Balveren, F van Hunsel
Drug safety 45 (4), 319-331, 2022
Vitamin B6 in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases
F van Hunsel, S van de Koppel, E van Puijenbroek, A Kant
Drug safety 41, 859-869, 2018
COVID-19 vaccine reactogenicity–A cohort event monitoring study in the Netherlands using patient reported outcomes
L Rolfes, L Härmark, A Kant, L van Balveren, W Hilgersom, F van Hunsel
Vaccine 40 (7), 970-976, 2022
Aim and design of pREGnant, the Dutch pregnancy drug register
S Vorstenbosch, B Te Winkel, MMHJ van Gelder, A Kant, N Roeleveld, ...
Drug Safety 42 (1), 1-12, 2019
Web-based intensive monitoring of adverse events following influenza vaccination in general practice
L van Balveren-Slingerland, A Kant, L Härmark
Vaccine 33 (19), 2283-2288, 2015
A ‘natural’weight loss product containing sibutramine
F van Hunsel, BJ Venhuis, PHJ Keizers, A Kant
Drug Testing and Analysis 8 (3-4), 311-314, 2016
The effect of the family physician on improving follow-up after an abnormal Pap smear
B Palm, AC Kant, EA Visser, GP Vooijs, W Van Den Bosch, C Van Weel
International Journal for Quality in Health Care 9 (4), 277-282, 1997
Preliminary results of a general practice based call system for cervical cancer screening in The Netherlands.
BT Palm, AC Kant, WJ van den Bosch, GP Vooijs, C van Weel
British journal of general practice 43 (377), 503-506, 1993
Measuring the impact of pharmacovigilance activities, challenging but important
F van Hunsel, H Gardarsdottir, A de Boer, A Kant
British Journal of Clinical Pharmacology 85 (10), 2235, 2019
General practitioner based screening for cervical cancer: higher participation of women with a higher risk?
AC Kant, B Palm, E Wentink, C Van Weel
Journal of Medical Screening 4 (1), 35-39, 1997
Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature
JW Duijster, T Lieber, S Pacelli, L Van Balveren, LS Ruijs, M Raethke, ...
Frontiers in immunology 14, 1078736, 2023
Numbers of spontaneous reports: how to use and interpret?
A Kant, F van Hunsel, E van Puijenbroek
British journal of clinical pharmacology 88 (3), 1365-1368, 2022
Cellular composition of cervical smears taken by general practitioners
AC Kant, B Palm, DJS Dona, AFC Makkus, GP Vooijs, C Weel
call system tor, 87, 1995
Implementation of the national cervical cancer screening in general practice and feasibility of a general practice-based call system: The GP's opinion
B Palm, AC Kant, W Van Den Bosch, CWB DE BEIJER, MEJ GERRITS, ...
Family practice 10 (2), 173-177, 1993
A call system for cervical cancer screening in the Netherlands organised on the basis of general practice
I Palm, A Kant, W van den Bosch, P Vooijs, C van Weel
The European Journal of General Practice 2 (3), 104-108, 1996
Optimizing safety surveillance for COVID-19 vaccines at the National Pharmacovigilance Centre Lareb: one year of COVID-19 vaccine experience
I Oosterhuis, J Scholl, E van Puijenbroek, A Kant, F van Hunsel
Drug Safety 46 (1), 65-75, 2023
CYP450 genotype and aggressive behavior on selective serotonin reuptake inhibitors
C Ekhart, M Matic, A Kant, E van Puijenbroek, R Schaik
Pharmacogenomics 18 (7), 613-620, 2017
Reflections after the Diane affair
A Kant, E van Puijenbroek, F van Hunsel
Journal of Thrombosis and Haemostasis 12 (9), 1385-1387, 2014
Reported adverse events following influenza vaccination
L van Balveren-Slingerland, HC Rümke, AC Kant
Nederlands Tijdschrift Voor Geneeskunde 158, A6841-A6841, 2014
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20